Medical AI

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

A new AI biomarker analyzes blood vessels in CT scans, offering earlier, more accurate predictions of which patients will benefit from immunotherapy.

The diagnostics firm has 180 days to boost its market value after a Nasdaq warning, placing immense pressure on its turnaround and high-stakes biosensor plans.

A landmark partnership aims to slash BCI development costs from $100M to $5M, accelerating therapies and the quest for a human brain AI model.

A $350,000 donation from prominent philanthropists will equip TGH's new Taneja Tower with a state-of-the-art iMRI, transforming brain surgery.

A new virotherapy platform delivers a one-two punch of a T-cell activator and a BiTE, aiming to overcome historical failures in solid tumor therapy.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

Dr. Batra's launches XODerma, a high-tech exosome skin therapy in Dubai, blending homeopathy with cellular science. But does the hype outpace regulation?

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

A new device blending light and sound therapy aims to give athletes a mental edge. But as BrainTap Sports enters the arena, can it prove its mettle?

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

Aktiia's Hilo adds sleep and step tracking to its validated blood pressure monitor, promising a holistic view of heart health in a competitive market.

Finnish medtech firm Bioretec reports staggering 2025 losses but bets its future on breakthrough implant technology and a complete strategic overhaul.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Helsinki pioneers a revolutionary cancer therapy, offering new hope with a targeted neutron beam that destroys tumors in just one or two sessions.